Isotopia Molecular Imaging and Molecular Targeting Technologies have signed a clinical supply agreement for Lu177 n.c.a.
That combination binds reversibly to circulating serum albumin, enhancing radiotherapeutic circulation half-life and delivering higher accumulation to targeted tumors.
177Lu is a beta-emitting radiopharmaceutical precursor with a half-life of 6.7 days and maximum energy of 0.5 MeV, corresponding to a maximum soft-tissue penetration of approximately 1 mm from its binding site. 177Lu is used in Precision Oncology for Targeted Radionuclide Therapy. It, precisely, destroys the tumor when bound to disease-specific, targeting therapeutics. Isotopia has developed a unique, stable, consistent and reliable GMP method to produce a highly pure form of 177Lu. n.c.a. Isotopia’s 177Lu contains no metastable 177mLu, eliminating cost intensive clinical waste management.
Isotopia’s CEO Dr. Eli Shalom stated, “Our strategy is to be partner to every leading pharmaceutical company developing Lu-177 n.c.a based products, supporting them from clinical trials through commercial sale. We are committed to produce 52 weeks per year, ensuring supply through long-term contracts. We’re patient-centric. Our two years of robust, reliable and flawless production enhances patient confidence. MTTI is a remarkable company which advances their vision for the development of new radiotherapeutics and Isotopia is proud to be part of it.”